354 related articles for article (PubMed ID: 23692386)
21. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
[TBL] [Abstract][Full Text] [Related]
22. Early risk stratification for diffuse large B-cell lymphoma integrating interim Deauville score and International Prognostic Index.
Yim SK; Yhim HY; Han YH; Jeon SY; Lee NR; Song EK; Jeong HJ; Kim HS; Kwak JY
Ann Hematol; 2019 Dec; 98(12):2739-2748. PubMed ID: 31712879
[TBL] [Abstract][Full Text] [Related]
23. [Prognostic significance of (18)F-fluorodeoxyglucose positron emission tomography in patients with diffuse large B cell lymphoma undergoing autologous stem cell transplantation].
Ying ZT; Mi L; Wang XJ; Zhang YW; Yang Z; Song YQ; Wang XP; Zheng W; Lin NJ; Tu MF; Xie Y; Ping LY; Zhang C; Liu WP; Deng LJ; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):382-386. PubMed ID: 29779346
[No Abstract] [Full Text] [Related]
24. Prognostic significance of bone marrow infiltration detected by PET-CT in newly diagnosed diffuse large B cell lymphoma.
Liang JH; Sun J; Wang L; Fan L; Chen YY; Qu XY; Li TN; Li JY; Xu W
Oncotarget; 2016 Apr; 7(14):19072-80. PubMed ID: 26919239
[TBL] [Abstract][Full Text] [Related]
25. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J
Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995
[TBL] [Abstract][Full Text] [Related]
26. Limited role of interim PET/CT in patients with diffuse large B-cell lymphoma treated with R-CHOP.
Yoo C; Lee DH; Kim JE; Jo J; Yoon DH; Sohn BS; Kim SW; Lee JS; Suh C
Ann Hematol; 2011 Jul; 90(7):797-802. PubMed ID: 21181163
[TBL] [Abstract][Full Text] [Related]
27. [Prognostic value of (18)F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma].
Ying ZT; Wang XJ; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ping LY; Liu WP; Deng LJ; Zhang C; Yang Z; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):810-3. PubMed ID: 23384899
[TBL] [Abstract][Full Text] [Related]
28. Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma.
Nols N; Mounier N; Bouazza S; Lhommel R; Costantini S; Vander Borght T; Vekemans MC; Sonet A; Bosly A; Michaux L; André M; Van Den Neste E
Leuk Lymphoma; 2014 Apr; 55(4):773-80. PubMed ID: 23927393
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis.
Burggraaff CN; de Jong A; Hoekstra OS; Hoetjes NJ; Nievelstein RAJ; Jansma EP; Heymans MW; de Vet HCW; Zijlstra JM
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):65-79. PubMed ID: 30141066
[TBL] [Abstract][Full Text] [Related]
30. Interim
Jiang M; Chen P; Ruan X; Ye X; Pan Y; Zhang J; Huang Q; Zhou W; Wu H; Wang Q
Oncol Lett; 2017 Dec; 14(6):6715-6723. PubMed ID: 29344120
[TBL] [Abstract][Full Text] [Related]
31. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of interim and posttherapy 18F-FDG PET/CT in patients with mature T-cell and natural killer cell lymphomas.
Li YJ; Li ZM; Xia XY; Huang HQ; Xia ZJ; Lin TY; Li S; Xia Y; Cai XY; Jiang WQ
J Nucl Med; 2013 Apr; 54(4):507-15. PubMed ID: 23397008
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of a [
Li M; Yao H; Zhang P; Zhang L; Liu W; Jiang Z; Li W; Zhao S; Wang K
Eur Radiol; 2023 May; 33(5):3354-3365. PubMed ID: 36547676
[TBL] [Abstract][Full Text] [Related]
34. Standardized uptake value for (18)F-fluorodeoxyglucose is correlated with a high International Prognostic Index and the presence of extranodal involvement in patients with diffuse large B-cell lymphoma.
Akkas BE; Vural GU
Rev Esp Med Nucl Imagen Mol; 2014; 33(3):148-52. PubMed ID: 24094371
[TBL] [Abstract][Full Text] [Related]
35. Early determination of prognosis by interim 3'-deoxy-3'-18F-fluorothymidine PET in patients with non-Hodgkin lymphoma.
Lee H; Kim SK; Kim YI; Kim TS; Kang SH; Park WS; Yun T; Eom HS
J Nucl Med; 2014 Feb; 55(2):216-22. PubMed ID: 24365650
[TBL] [Abstract][Full Text] [Related]
36. Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma.
Baratto L; Davidzon GA; Moghbel M; Hatami N; Iagaru A; Mittra ES
Clin Nucl Med; 2018 Jan; 43(1):1-8. PubMed ID: 29076913
[TBL] [Abstract][Full Text] [Related]
37. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
Yang Y; Wang L; Ma Y; Han T; Huang M
Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
[TBL] [Abstract][Full Text] [Related]
38. Midtreatment ¹⁸F-FDG PET/CT Scan for Early Response Assessment of SMILE Therapy in Natural Killer/T-Cell Lymphoma: A Prospective Study from a Single Center.
Khong PL; Huang B; Lee EY; Chan WK; Kwong YL
J Nucl Med; 2014 Jun; 55(6):911-6. PubMed ID: 24819420
[TBL] [Abstract][Full Text] [Related]
39. The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission.
Lerner RE; Thomas W; Defor TE; Weisdorf DJ; Burns LJ
Biol Blood Marrow Transplant; 2007 Apr; 13(4):486-92. PubMed ID: 17382255
[TBL] [Abstract][Full Text] [Related]
40. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
